<DOC>
	<DOC>NCT00202605</DOC>
	<brief_summary>The purpose of the study is to evaluate how safe and how well SPD465 works compared to placebo in adults with ADHD. It is hypothesized that SPD465 will achieve an extended duration of clinical benefit.</brief_summary>
	<brief_title>Safety and Efficacy of SPD465 in Adults With ADHD</brief_title>
	<detailed_description />
	<mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Amphetamine</mesh_term>
	<mesh_term>Dextroamphetamine</mesh_term>
	<criteria>Primary diagnosis of ADHD using DSMIVTR criteria (at least 6 of the 9 subtype criteria met) Baseline ADHDRSIV score =&gt;24 IQ score of =&gt; 80 (using Kaufman Brief Intelligence Test) BMI &lt; 18.5 or &gt; 30 kg/m2 Diagnosis of Post Traumatic Stress Disorder, psychosis, bipolar illness, severe obsessive compulsive disorder, severe depressive or severe anxiety disorder History of seizure disorder or a lifetime history of any seizures (other than infantile febrile seizures), any tic disorder, or a current diagnosis and/or family history of Tourette's Disorder History of uncontrolled hypertension or currently hypertensive Subjects who have taken atomoxetine (STRATTERA) within 30 days prior to screening Current (or history within the last 12 months) of drug dependence or substance abuse disorder according to DSMIVTR criteria (excluding nicotine) Female subject is pregnant or lactating, less than 3 months post partum</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2007</verification_date>
</DOC>